Integrated BioPharma 3Q 2026: Revenue $9.91M, EPS ($0.02) — 10-Q Summary
Integrated BioPharma reported 3Q 2026 revenue of $9.91M, down 21.9% YoY, with a net loss of $691K compared to a prior-year profit. Decreased sales volumes, especially to Life Extension, and lower margins contributed to the decline. Management expects operations and credit facilities to support working capital through November 2027.
How this was made
The 30-second read
Why it matters
The earnings shortfall may trigger a sell‑off, but the company’s credit facility could stabilize cash flow through next year.
Market read
Micro‑cap earnings miss with limited broader market effect.
What to watch
Potential upside from the $107K increase in sales to Herbalife and any future contract wins not disclosed.
Background
Integrated BioPharma is a contract manufacturer serving biotech and nutrition brands; its Q3 filing shows a sharp revenue decline.
Ticker impact
Integrated BioPharma reported Q3 2026 revenue of $9.91M, a 21.9% YoY decline, and a net loss of $0.69M.
likely downward pressure as investors price in weaker sales and loss
The company’s revenue contraction and loss suggest reduced profitability, prompting sell pressure.
Market effects
Highlights challenges in contract manufacturing for biotech firms reliant on single large customers.
Minimal impact; the company is a micro‑cap with limited market breadth.
Low; the earnings miss is unlikely to affect broader market sentiment.
Counterpoint
If the revolving credit facility provides sufficient liquidity, the stock could rebound on a short‑term buying opportunity.
Key entities
- companyIntegrated BioPharma Inc.
Biotech contract manufacturer reporting Q3 2026 results.
